SYRS — Syros Pharmaceuticals, Inc.

Summary of Syros Pharmaceuticals Q3 2024 Earnings Call

1. Key Financial Results and Metrics

• Revenue: No revenue recognized in Q3 2024, down from $3.8 million in Q3 2023 due to the termination of a collaboration agreement with Pfizer.
• R&D Expenses: $20.5 million in Q3 2024, a decrease from $28.3 million in Q3 2023, attributed to reduced external R&D costs and headcount.
• G&A Expenses: $5.7 million in Q3 2024, down from $7.8 million in Q3 2023, primarily due to lower headcount and consulting expenses.
• Net Loss: $6.4 million, or $0.16 per share, compared to a net loss of $40.1 million, or $1.43 per share, in Q3 2023.
• Cash Position: $58.3 million as of September 30, 2024, down from $79 million at the end of Q2 2024, expected to fund operations into Q3 2025.

2. Strategic Updates and Business Highlights

• Tamibarotene Development: Focused on developing tamibarotene as a new standard of care for higher-risk MDS patients with RARA gene overexpression, representing a significant market opportunity.
• SELECT-MDS-1 Trial: Pivotal data readout expected in mid-November 2024, with the primary endpoint being the complete response (CR) rate in a Phase 3 trial comparing tamibarotene plus azacitidine to placebo plus azacitidine.
• Market Opportunity: Anticipated U.S. market for higher-risk MDS therapeutics could reach approximately $1.6 billion by 2029, with tamibarotene's potential market share exceeding $800 million.

3. Forward Guidance and Outlook

• NDA Filing: Plans to file a New Drug Application (NDA) post-data release, with a focus on ensuring all data is validated and regulatory interactions are routine.
• Commercial Preparation: Ongoing efforts to prepare for the commercial launch of tamibarotene, including market awareness initiatives and infrastructure development.

4. Bad News, Challenges, or Points of Concern

• Revenue Decline: The absence of revenue due to the termination of the Pfizer collaboration raises concerns about immediate financial stability.
• Cash Burn: The reduction in cash reserves from Q2 to Q3 2024 highlights the need for careful financial management as the company approaches its NDA filing.
• Market Competition: The existing therapies for higher-risk MDS, particularly hypomethylating agents, present a competitive landscape that may impact the adoption of tamibarotene.

5. Notable Q&A Insights

• Efficacy Benchmarks: Management reiterated that the CR rate for azacitidine serves as a benchmark for interpreting tamibarotene's potential efficacy, with historical rates around 17%.
• Safety Profile: Emphasis on the importance of a favorable safety profile for tamibarotene, particularly for elderly patients with comorbidities.
• Commercial Strategy: Plans for post-data release include accelerating commercial preparations and ensuring broad access to tamibarotene.
• Future of 5609: The CDK7 asset (5609) is considered high-potential but may be better suited for a larger pharma partner, indicating ongoing business development efforts for this asset.

Overall, Syros Pharmaceuticals is at a critical juncture with the upcoming pivotal trial data for tamibarotene, which could significantly impact its future trajectory and market positioning in the treatment of higher-risk MDS.